Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 5M | 10M | 0 | 0 |
| Gross Profit | -21K | 5M | 10M | 0 | 0 |
| Operating Income | -37M | -56M | -52M | -47M | -42M |
| EBITDA | -37M | -53M | -47M | -46M | -42M |
| Net Income | -39M | -53M | -48M | -46M | -42M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$52.36
+7.38% today
1Y Change
+897.33%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Spruce Biosciences, Inc. (SPRB) is a Healthcare stock with a market cap of $80.00M and listed on NASDAQ. The stock last traded around $52.36 and up 897.3% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +47.5%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +47.5%, free cash flow +40.4% with operating margin 0.0% and ROIC -84.4%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SPRB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SPRB
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SPRB Max Drawdown
-98.96%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SPRB and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$42.3M
+8.4% YoY
Free Cash Flow
-$36.0M
+13.7% YoY
Revenue Growth
-100.0%
EPS Growth
+47.5%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 5M | 10M | 0 | 0 |
| Gross Profit | -21K | 5M | 10M | 0 | 0 |
| Operating Income | -37M | -56M | -52M | -47M | -42M |
| EBITDA | -37M | -53M | -47M | -46M | -42M |
| Net Income | -39M | -53M | -48M | -46M | -42M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 49M | 39M | 96M | 24M | 43M |
| Total Assets | 53M | 45M | 104M | 86M | 126M |
| Total Liabilities | 11M | 16M | 27M | 17M | 15M |
| Shareholder Equity | 43M | 29M | 77M | 68M | 111M |
| Total Debt | 736K | 3M | 5M | 6M | 7M |
| Net Debt | -48M | -36M | -92M | -18M | -36M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
36M
+13.9% YoY
Capital Expenditures
93K
-1062.5% YoY
Free Cash Flow
36M
+13.7% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-204.0%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.